• Vaccine Ontology ID: VO_0011537
• Type: Recombinant vector vaccine
• Status: Research
• M matrix protein gene engineering:
  • Type: Recombinant vector construction
  • Detailed Gene Information: Click Here.
• Vector: Vaccinia Virus (Brinckmann et al., 1991).
• Immunization Route: Intraperitoneal injection (i.p.)

• Vaccine Ontology ID: VO_0011535
• Type: Recombinant vector vaccine
• Status: Research
• N nucleocapsid protein gene engineering:
  • Type: Recombinant vector construction
  • Detailed Gene Information: Click Here.
• Vector: Vaccinia virus (Brinckmann et al., 1991).
• Immunization Route: Intraperitoneal injection (i.p.)

• Vaccine Ontology ID: VO_0011536
• Type: Recombinant vector vaccine
• Status: Research
• P phosphoprotein gene engineering:
  • Type: Recombinant vector construction
  • Detailed Gene Information: Click Here.
• Vector: Vaccinia virus (Brinckmann et al., 1991).
• Immunization Route: Intraperitoneal injection (i.p.)

Rat Response

• Host Strain: Lewis
• Vaccination Protocol: To determine the protective effect of individual measles virus (MV) proteins, 2- to 3-week-old suckling rats were immunized either once, twice or three times at 5 to 7 day intervals by i.p. injections of 10⁷ p.f.u, of recombinant vaccinia virus (VV) expressing individual structural proteins or VV-wt (Brinckmann et al., 1991).
• Challenge Protocol: Three to 5 days after the last recombinant VV injection, the animals were challenged by intracerebral (i.c.) infection with the neurotropic rat brain-adapted MV strain CAM/RBH (0.5 × 10⁴ to 8 x 10 ~ TCID50) (Brinckmann et al., 1991).
• Efficacy: Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVM (Matrix Protein) -immunized rats were partially protected from MV challenge (Brinckmann et al., 1991).

Rat Response

• Host Strain: Lewis
• Vaccination Protocol: To determine the protective effect of individual measles virus (MV) proteins, 2- to 3-week-old suckling rats were immunized either once, twice or three
  times at 5 to 7 day intervals by i.p. injections of 10⁷ p.f.u, of recombinant vaccinia virus (VV) expressing individual structural proteins or VV-wt (Brinckmann et al., 1991).
• Challenge Protocol: Three to 5 days after the last recombinant VV injection, the animals were challenged by intracerebral (i.c.) infection with the neurotropic rat brain-adapted MV strain CAM/RBH (0.5 × 10⁴ to 8 x 10 ~ TCID50) (Brinckmann et al., 1991).
• Efficacy: Rats immunized with recombinant VVN survived a MV challenge infection (Brinckmann et al., 1991).

Rat Response

• Host Strain: Lewis
• Vaccination Protocol: To determine the protective effect of individual measles virus (MV) proteins, 2- to 3-week-old suckling rats were immunized either once, twice or three times at 5 to 7 day intervals by i.p. injections of 10⁷ p.f.u, of recombinant vaccinia virus (VV) expressing individual structural proteins or VV-wt (Brinckmann et al., 1991).
• Challenge Protocol: Three to 5 days after the last recombinant VV injection, the animals were challenged by intracerebral (i.c.) infection with the neurotropic rat brain-adapted MV strain CAM/RBH (0.5 × 10⁴ to 8 x 10 ~ TCID50) (Brinckmann et al., 1991).
• Efficacy: Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVP (Phosphoprotein) -immunized rats were partially protected from MV challenge (Brinckmann et al., 1991).